Background
Methods
Study design
Primary, secondary objectives, and safety results
Statistical analysis
Results
Study population
Baseline characteristics and angiographic and PCI findings
Variables | Group A | Control C1 | p Value | Control C2 | p Value | p Value |
---|---|---|---|---|---|---|
(A vs C1) | (C1vs C2) | (A vs C2) | ||||
Demographic characteristics | ||||||
Men (%) | 17 (56.7%) | 25 (83.3%) | 0.048 | 67 (85.9%) | 0.973 | 0.002 |
Age (years) | 70.0 ± 12.8 | 64.5 ± 12.0 | 0.091 | 62.9 ± 10.1 | 0.486 | 0.003 |
Body mass index (kg/m2) | 25.1 ± 3.0 | 24.6 ± 2.0 | 0.474 | 25.2 ± 3.1 | 0.852 | 0.320 |
Diabetes | 14 (46.7%) | 8 (26.7%) | 0.180 | 17 (21.8%) | 0.777 | 0.020 |
Hypertension | 19 (63.3%) | 17 (56.7%) | 0.792 | 35 (44.9%) | 0.376 | 0.132 |
Medication at ER | ||||||
Aspirin loading | 27 (90.0%) | 22 (73.3%) | 0.182 | 70 (89.7%) | 0.064 | 1.000 |
Clopidogrel loading | 27 (90.0%) | 27 (90.0%) | 1.000 | 76 (97.4%) | 0.256 | 0.256 |
Beta blocker | 26 (89.7%) | 23 (76.7%) | 0.326 | 71 (91.0%) | 0.095 | 1.000 |
ACEI/ARB | 23 (79.3%) | 25 (83.3%) | 0.950 | 63 (80.8%) | 0.975 | 1.000 |
CCB | 1 (3.4%) | 1 (3.3%) | 1.000 | 13 (16.7%) | 0.126 | 0.139 |
Statin | 28 (96.6%) | 30 (100.0%) | 0.986 | 77 (98.7%) | 1.000 | 1.000 |
Major laboratory findings | ||||||
Hematocrit (%) | 39.7 ± 5.8 | 41.3 ± 4.3 | 0.107 | 43.5 ± 4.4 | 0.022 | 0.000 |
Platelet (×103/μl) | 213.6 ± 49.0 | 226.1 ± 63.2 | 0.396 | 220.9 ± 47.0 | 0.639 | 0.483 |
Total cholesterol (mg/dl) | 162.9 ± 35.6 | 176.1 ± 51.1 | 0.261 | 189.9 ± 38.5 | 0.132 | 0.002 |
Triglyceride (mg/dl) | 129.6 ± 85.7 | 133.5 ± 92.6 | 0.867 | 133.1 ± 81.1 | 0.982 | 0.848 |
LDL cholesterol (mg/dl) | 98.4 ± 40.3 | 100.2 ± 36.5 | 0.861 | 116.9 ± 33.5 | 0.029 | 0.022 |
Serum creatinine (mg/dl) | 0.9 ± 0.6 | 0.9 ± 0.2 | 0.819 | 0.8 ± 0.2 | 0.262 | 0.331 |
Ejection fraction (%) | 57.1 ± 9.1 | 59.8 ± 6.2 | 0.201 | 59.6 ± 6.5 | 0.852 | 0.134 |
P2Y12 reaction units | 277.2 ± 39.2 | 281.4 ± 38.4 | 0.672 | 171.1 ± 51.6 | 0.000 | 0.000 |
Variables | Group A | Control C1 | p Value | Control C2 | p Value | p Value |
---|---|---|---|---|---|---|
(A vs C1) | (C1vs C2) | (A vs C2) | ||||
Lesion characteristics | ||||||
Multivessel PCI | 13 (43.3%) | 9 (30.0%) | 0.421 | 25 (32.1%) | 1.000 | 0.381 |
Target vessel | ||||||
Left main disease | 0 (0.0%) | 1 (3.3%) | 1.000 | 5 (6.4%) | 0.875 | 0.378 |
Left anterior descending artery | 18 (60.0%) | 19 (63.3%) | 1.000 | 47 (60.3%) | 0.941 | 1.000 |
Left circumflex artery | 11 (36.7%) | 11 (36.7%) | 1.000 | 31 (49.7%) | 0.941 | 0.941 |
Right coronary artery | 11 (36.7%) | 11 (36.7%) | 1.000 | 20 (25.6%) | 0.370 | 0.370 |
IVUS guidance | 9 (31.0%) | 4 (13.3%) | 0.184 | 21 (26.9%) | 0.213 | 0.858 |
Type B2/C lesion | 36 (73.5%) | 35 (79.5%) | 0.657 | 90 (81.8%) | 0.922 | 0.323 |
Restenotic lesion | 2 (2.3%) | 1 (4.3%) | 1.000 | 0 (0.0%) | 0.634 | 0.161 |
Angiographic thrombus | 13 (43.3%) | 11 (36.7%) | 0.792 | 30 (38.5%) | 1.000 | 0.807 |
Procedure characteristics | ||||||
Stents per target lesion (n) | 1.20 ± 0.41 | 1.09 ± 0.29 | 0.124 | 1.05 ± 0.23 | 0.460 | 0.009 |
Stent type | ||||||
Drug eluting balloon | 1 | 0 | 0 | |||
Bare metal stent | 0 | 1 | 0 | |||
Drug-eluting stent | 53 | 47 | 117 | |||
Stent size | 2.70 ± 0.47 | 2.79 ± 0.46 | 0.651 | 2.84 ± 0.45 | 0.409 | 0.737 |
Stent length | 23.7 ± 8.7 | 21.8 ± 5.5 | 0.548 | 23.0 ± 8.7 | 0.613 | 0.838 |
Duration of loading time to the procedure | 34.0 ± 18.6 | 29.9 ± 18.3 | 0.480 | 29.4 ± 16.1 | 0.917 | 0.270 |
Emergency PCI | 1 | 1 | 0 |